Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Global First Approval For Takeda's Dengue Vaccine, In Indonesia

Set To Open Door To Wider Vaccine Use?

Executive Summary

Takeda’s dengue vaccine Qdenga has received its global first approval in Indonesia, as Qdenga, also marking the first time for the firm to market a vaccine outside Japan and potentially paving the way to wider global use of vaccines for the mosquito-borne disease following setbacks for earlier contenders. 

You may also be interested in...



Takeda Sees Mainstays Tiding It Over Upcoming Expiries

As Takeda reported what its CEO described as "a remarkable year," the company sees itself as well positioned to ride out the expiries over the next few years of exclusivity for several big-selling products, as it looks to mainstays and more organic growth to tide it over the "temporary headwinds."

Takeda Still Hopeful On Dengue Vaccine Candidate

Takeda says loss of accelerated assessment status at EMA for marketing authorization application for its dengue vaccine candidate TAK-003 “was anticipated as a potential outcome.”

Takeda To Build On COVID-19 Awareness For Its Dengue Vaccine

Takeda’s vaccines chief Rajeev Venkayya tells Scrip about its COVID-19 vaccines partnerships, and how the pandemic can stimulate action against other infectious disease threats such as Dengue.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146936

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel